Who should receive the shingles vaccine?

Revision as of 19:30, 11 January 2009 by Johnfanisrour (talk | contribs) (New page: ==Immunity decreses with age== More than 1 million cases are estimated to occur in the USA. The Elderly population is at risk because the immunity toVZV decreases with aging. More tha...)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Immunity decreses with age

More than 1 million cases are estimated to occur in the USA. The Elderly population is at risk because the immunity toVZV decreases with aging. More than 50% of people who reach age above 85 develop shingles at some point and 20 % of these patients develop postherptic neuralgia.

Is vaccination effective?

The shingles prevention study includeed more than 38,000 adults with median age of 69 years with a follow up for a mean of 3.13 years after receiving the vaccine. The vaccination significantly reduced the incidence of zoster by 51 %(p<.001), and the incidence of of postherptic neuralgia by 66%. The live attenuated vaccine did not result is acute shingles in vaccinated subjects. If lesions did occur, they were from the patient's own antive strain.

Is it imoportant that the vaccination decreases postherptic neuralgia?

Yes.

Retrieved from "https://www.wikidoc.org/index.php?title=Who_should_receive_the_shingles_vaccine%3F&oldid=523320"